Alfred Altomari insider trades: Agile Therapeutics (AGRX) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Alfred reports to the SEC
and 1 more company
Open-market buys and sales
21 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 26, 2022 | AGRX | ↑ Buy | 50,000 | $0.45 | $23K | Direct | Aug 29, 2022 (3d) |
| Jul 29, 2021 | AGRX | ↑ Buy | 26,200 | $1.26 | $33K | Direct | Jul 29, 2021 (0d) |
| May 18, 2021 | AGRX | ↑ Buy | 20,000 | $1.61 | $32K | Direct | May 19, 2021 (1d) |
| Mar 23, 2021 | AGRX | ↑ Buy | 12,500 | $2.00 | $25K | Direct | Mar 23, 2021 (0d) |
| Dec 7, 2020 | INSM | ↓ Sell | 20,000 | $39.57 | $791K | Direct | Dec 9, 2020 (2d) |
| Nov 23, 2020 | BXRX | ↑ Buy | 5,000 | $1.06 | $5K | Direct | Nov 24, 2020 (1d) |
| Mar 26, 2020 | BXRX | ↑ Buy | 5,000 | $2.34 | $12K | Direct | Mar 27, 2020 (1d) |
| Feb 27, 2020 | AGRX | ↑ Buy | 10,000 | $2.71 | $27K | Direct | Feb 27, 2020 (0d) |
| Jun 10, 2019 | AGRX | ↑ Buy | 20,000 | $1.27 | $25K | Direct | Jun 11, 2019 (1d) |
| Mar 25, 2019 | AGRX | ↑ Buy | 25,000 | $1.54 | $39K | Direct | Mar 26, 2019 (1d) |
| Feb 26, 2019 | INSM | ↓ Sell10b5-1 | 5,500 | $30.00 | $165K | Direct | Feb 27, 2019 (1d) |
| Feb 15, 2019 | INSM | ↓ Sell10b5-1 | 5,500 | $27.50 | $151K | Direct | Feb 20, 2019 (5d) |
| Feb 5, 2019 | INSM | ↓ Sell10b5-1 | 5,500 | $25.00 | $138K | Direct | Feb 7, 2019 (2d) |
| Jan 10, 2019 | INSM | ↓ Sell10b5-1 | 5,500 | $22.50 | $124K | Direct | Jan 14, 2019 (4d) |
| Aug 25, 2017 | AGRX | ↑ Buy | 10,000 | $3.34 | $33K | Direct | Aug 28, 2017 (3d) |
| May 11, 2017 | AGRX | ↑ Buy | 10,000 | $3.51 | $35K | Direct | May 12, 2017 (1d) |
| Dec 15, 2016 | REPH | ↑ Buy | 1,500 | $6.55 | $10K | Direct | Dec 16, 2016 (1d) |
| Jun 2, 2015 | AGRX | ↑ Buy | 2,500 | $8.73 | $22K | Direct | Jun 3, 2015 (1d) |
| Aug 11, 2011 | DUSA | ↑ Buy | 2,000 | $4.06 | $8K | Direct | Aug 11, 2011 (0d) |
| Aug 5, 2010 | DUSA | ↑ Buy | 2,000 | $2.52 | $5K | Direct | Aug 5, 2010 (0d) |
| May 8, 2007 | AUXL | ↓ Sell | 15,000 | $13.33 | $200K | Direct | May 10, 2007 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Alfred Altomari's insider trades
Alfred Altomari is Chief Executive Officer at Agile Therapeutics (AGRX). Since May 8, 2007, Alfred has reported 15 open-market purchases worth $334K and 6 sales worth $1.6M on SEC Form 4. There have been no open-market trades in the last 12 months.
4 sales (37% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (48 filings), option exercises (14 filings), shares returned to the company (3 filings), other transactions (3 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AGRX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.